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Abstract
Defects in HLA class I antigen-processing machinery (APM) component expression and/or function are frequent in
human tumors. These defects may provide tumor cells with a mechanism to escape from recognition and destruc-
tion by HLA class I antigen-restricted, tumor antigen–specific cytotoxic T cells. However, expression and functional
properties of MHC class I antigens and APM components in malignant cells in other animal species have been
investigated to a limited extent. However, this information can contribute to our understanding of the mechanisms
underlying the association of MHC class I antigen and APM component defects with malignant transformation of
cells and to identify animal models to validate targeted therapies to correct these defects. To overcome this lim-
itation in the present study, we have investigated the expression of the catalytic subunits of proteasome (Y, X, and
Z) and of immunoproteasome (LMP2, LMP7, and LMP10) as well as of MHC class I heavy chain (HC) in 25 primary
feline mammary carcinomas (FMCs) and in 23 matched healthy mammary tissues. We found a reduced expression
of MHC class I HC and of LMP2 and LMP7 in tumors compared with normal tissues. Concordantly, proteasomal
cleavage specificities in extracts from FMCs were different from those in healthy tissues. In addition, correlation
analysis showed that LMP2 and LMP7 were concordantly expressed in FMCs, and their expression was signifi-
cantly correlated with that of MHC class I HC. The abnormalities we have found in the APM in FMCs may cause a
defective processing of some tumor antigens.
Translational Oncology (2012) 5, 48–55
Introduction
The recognition of tumor cells by MHC class I antigen-restricted,
tumor antigen (TA)–specific cytotoxic T lymphocytes is mediated
by β2-microglobulin (β2-m)-MHC class I heavy chains (HCs)–TA-
derived peptide complexes. The generation and expression of these
trimolecular complexes on the cell membrane requires the integrity
of three essential pathways: 1) the degradation of proteins into peptides
in the cytoplasm, 2) the transport of the peptides into the endoplasmic
reticulum, and 3) the peptide loading on nascent MHC class I mole-
cules as well as their transport to the cell surface [1]. The peptides
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presented by MHC class I antigens are generated by the degradation of
ubiquitin-marked intracellular proteins by the proteasome, a multi-
meric proteolytic complex; its β-subunits delta (Y), MB1 (X), and Z
are responsible for its catalytic activity [2,3]. When cells are incubated
with interferon-γ (IFN-γ), the three catalytic subunits Y, X, and Z of
the proteasome are replaced by the low-molecular-weight proteins
LMP2, LMP7, and LMP10, respectively, leading to the replacement
of constitutive proteasome with the so-called immunoproteasome [4].
It is well established that the presence of these IFN-γ–induced subunits
changes catalytic activity against model peptide substrates. They en-
hance cleavages after hydrophobic, basic, and branched chain residues
but suppress cleavages after acidic residues. Therefore, immunopro-
teasomes generate a different spectrum of oligopeptides compared with
proteasomes. This type of peptides has been proposed to enhance
antigen presentation [5] because the transporter associated with antigen
processing (TAP) and MHC class I molecules preferentially bind pep-
tides with carboxyl-terminal hydrophobic and basic residues over those
with acidic residues.
Convincing experimental evidence has shown that malignant
transformation of cells is frequently associated with defects in the
expression of antigen-processing machinery (APM) components
and HLA class I antigens in humans [6–8]. These defects may have
functional significance because they may provide tumor cells with a
mechanism to escape from recognition and destruction by HLA class
I antigen-restricted, TA-specific cytotoxic T cells [9–16]. Further-
more, they may have clinical significance because they are often asso-
ciated with the histopathologic characteristics of the lesions and/or
with the clinical course of the disease [17–20]. Nevertheless, the
expression and functional properties of MHC class I antigens and
APM components in malignant cells in other animal species have
been investigated to a limited extent. However, this information
can contribute to our understanding of the mechanisms underlying
the association of MHC class I antigen and APM component defects
with malignant transformation of cells and to identify animal models
to validate targeted therapies to correct these defects. To overcome
this limitation in the present study, we have investigated the expres-
sion of the catalytic subunits of proteasome (Y, X, and Z) and of
immunoproteasome (LMP2, LMP7, and LMP10) as well as of
MHC class I HC in 25 primary feline mammary carcinomas (FMCs)
and in 23 matched healthy mammary tissues. FMC has been selected
for our studies because it is the third most common neoplasm in cats
and is an informative model for the study of tumor biology in other
species, including humans. Furthermore, we have tested the func-
tional properties of proteasome and immunoproteasome in extracts
of FMC lesions.
Materials and Methods
Patients and Tissue Samples
Mammary tumors and normal tissues. Twenty-five primary
FMCs and 23 matched normal mammary epithelium were collected
in total. Paraffin wax blocks of 16 mammary tumor tissues with 14
matched normal mammary epithelium were retrieved from the
archives of our laboratory. Each block was reviewed by a pathologist
(T.M.) to confirm the diagnosis, and mammary tumors were catego-
rized according to the type of carcinoma (complex, simple solid,
simple tubulopapillary, anaplastic, or others). Mammary tumor sam-
ples came from primary masses removed for therapeutic purposes at
our hospital or other referring hospitals. In the course of the described
studies, an additional nine surgical samples of primary mammary tumor
and corresponding normal mammary tissue were collected, with the
owners’ consent. A portion of each tissue sample was fixed in 4% buff-
ered formalin and embedded in paraffin following standard procedures,
and a second portion was snap frozen for proteasome activity assay.
Samples were stored at −80°C until use.
The mammary tumors collected included 16 simple tubular carci-
nomas, 4 simple tubulopapillary carcinomas, 3 simple solid carcinomas,
and 1 adenocarcinoma. Four of the mammary tumors examined were
known to have regional lymph node metastasis. Of the 25 cats with
mammary masses, 18 were sexually intact females, aged 8 to 18 years.
Monoclonal Antibodies
The mouse monoclonal antibody (mAb) HC-10, which recognizes a
determinant expressed on all of the β2m-free HLA-B HCs and on β2m-
free HLA-A10, -A28, -A29, -A30, -A31, -A32, and -A33 HCs [21,22];
the LMP2-specific mAb SY-1 [23]; the LMP7-specific mAbHB-2 [23],
the LMP10-specific mAbTO-7 [23]; the Y-specific mAb SY-5 [23]; the
X-specific mAb SJJ-3 [23]; and the Z-specific mAb NB-1 [23], were
developed and characterized as described. mAbs were purified from
ascitic fluid by sequential precipitation with ammonium sulfate and
caprylic acid [24]. Purity and activity of mAb preparations were mon-
itored by SDS-PAGE and by reactivity with the corresponding antigens
in Western blot analysis.
Immunohistochemical Staining
Immunoperoxidase staining of tissue sections was performed using
the EnVision+ system (DakoCytomation, Carpinteria, CA). Briefly,
5-μm-thick paraffin-embedded tissue sections were deparaffinized
with xylene and rehydrated by passage through decreasing concentra-
tions of ethanol. Tissue sections were incubated for 40 minutes at
98°C in citrate solution, pH 6.0, for antigen retrieval. Then tissue
sections were incubated with 3% H2O2 in methanol for 15 minutes
at room temperature to block endogenous peroxidase activity. After
repeated rinsing with phosphate-buffered saline solution (PBS), tissue
sections were incubated overnight at 4°C with an optimal amount of
mAb. To reduce the background staining, mAb preparations were
diluted with PBS supplemented with 10% bovine serum albumin
(BSA). After washing, tissue sections were incubated for 30 minutes
at room temperature with the EnVision+ reagent. Staining was visualized
using the liquid 3,3′-diaminobenzidine substrate-chromogen system
(DakoCytomation). Tissue sections were counterstained for 2 minutes
with Mayer hematoxylin solution. The percentage of stained tumor cells
in each lesion was evaluated independently by two investigators (A.F.
and M.T.). Variations in the percentage of stained cells enumerated
by the two investigators were within a 10% range. In consideration of
the error, we evaluated the percentage of stained tumor cells at 10%
levels. Normal lymphocytes and vessel endothelium were used in each
specimen as internal positive controls. Negative controls were performed
by omitting primary antibodies. Results were scored as (+), (±), and (−)
when the percentage of stained cells in the tissue was more than 75%,
25% to 75%, and less than 25%, respectively, according to the criterion
established by the HLA and Cancer component of the 12th Interna-
tional Histocompatibility Workshop [25].
Total Proteins
Samples of mammary carcinoma and healthy mammary gland were
collected from the same animal during surgery, frozen, homogenized in
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ice-cold extraction buffer (50mMTris-HCl pH7.5, 1mMdithiothreitol,
250 mM sucrose, 5 mMMgCl2, 0.5 mM EDTA, 2 mM ATP) using an
ultraturax DIAX900 homogenizer (Heidolph Instruments, Kelheim,
Germany) and centrifuged at 3616g for 20 minutes at 4°C. The protein
concentration in supernatants was determined using the QUICK START
Bradford Dye Reagent 1× (Biorad, Hercules, CA) using a standard curve
constructed with BSA. Samples were stored at −80°C until use.
Immunoblot Analyses
Immunoblot analyses of the immunoproteasomal catalytic β sub-
units, LMP2, LMP7, and LMP10 in both carcinomas and healthy
mammary tissues extracts were performed as already described [26].
Briefly, 60 μg of total proteins was separated on a 12% SDS-PAGE gel,
and proteins were transferred on a Hybond-P membrane (Amersham
Pharmacia, Buckinghamshire, United Kingdom). Membranes were
stained with Ponceau Red before incubating with the primary antibody
to confirm that similar amounts of proteins had been transferred. The
membrane was then incubated in a blocking buffer (2% BSA in 1×
PBS; 0.1% Tween-20), followed by incubation with rabbit antisera
against LMP2 and LMP7 (a kind gift from Dr K. Tanaka, Tokyo
Metropolitan Institute ofMedical Science, Tokyo, Japan) and withmouse
monoclonal anti-LMP10 Ab TO-7 (a kind gift from Prof Ferrone).
Figure 1. Immunohistochemical staining of MHC class I HCs and antigen-processing machinery (APM) components in normal mammary
gland tissue. Sections of formalin-fixed, paraffin-embedded, healthy mammary gland tissue were stained in immunoperoxidase reaction
with mouse anti–MHC class I HC (A), anti-LMP2- (B), anti-LMP7- (C), anti-LMP10- (D), anti-Y- (E), anti-X- (F), and anti-Z- (G) specific anti-
bodies. The sections were then counterstained withMayer hematoxylin solution. Surface epithelia are homogeneously stained by the seven
antibodies. Whereas anti-MHC class I was localized at the cell surface, antiproteasome and immunoproteasome catalytic subunits staining
was localized in the cytoplasm and/or nuclei. Original magnification, ×400.
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Bound antibodies were visualized using the ECL technique (ECLPlus
Western Blotting Detection Reagents; Amersham Pharmacia).
Proteasome Activity Assays
Peptidase activities of proteasomes were assayed by monitoring the
production of 7-amino-4-methylcoumarin (amc) from fluorogenic
peptides as previously described [27]. Briefly, Suc-LLVY-amc (for
the chymotrypsin-like activity) and Z-YVAD-amc (for the caspase-
like activity) (BACHEM, Bubendorf, Switzerland) were used at a
final concentration of 100 μM in 20 mM Tris-HCl pH 7.5, 1 mM
ATP, 2 mM MgCl2 and 0.2% BSA. Reactions were started by adding
an aliquot of tissue extract and the fluorescence of released amc (exci-
tation, 380 nm; emission, 460 nm) was monitored continuously at 37°C
with a Carry Eclipse spectrofluorimeter (VARIAN, Palo Alto, CA).
Background activity (caused by nonproteasomal degradation) was
determined by adding the proteasome inhibitor MG132 (BACHEM)
at a final concentration of 10 μM. Specific proteasomal activity was
therefore calculated as the fraction of the total activity that could be
inhibited by MG132.
Statistical Analysis
Correlation of APM component expression among themselves and
with MHC class I HC expression was analyzed using the Spearman
rank correlation coefficient. Furthermore, the Wilcoxon test was used
to establish if the chymotrypsin-like and caspase-like activities differed
significantly between mammary carcinoma and healthy mammary
gland. Data were graphically visualized using box plots.
P < .05 was considered statistically significant.
Results
Constitutive Expression of MHC Class I APM Components
in Normal Mammary Epithelium
Because the constitutive expression profile of the different APM
components in normal mammary epithelium is not known, all the
antibodies were first tested on formalin-fixed, paraffin-embedded,
healthy mammary gland tissues. As shown in Figure 1, mammary
gland epithelium was homogeneously stained by all the antibodies
tested. The proteasome subunits and IFN-γ–inducible proteasome
subunits LMP2, LMP7, and LMP10 were strongly expressed in the
cytoplasm and nuclei of normal mammary cells, whereas immuno-
histochemical staining with the MHC class I HC-specific mAb HC-10
resulted in a cytoplasmic/membranous staining. Table 1 summarizes the
results obtained by immunoperoxidase staining of 23 healthy mammary
gland samples with the panel of APM component-specific mAb tested.
Differential Expression of Proteasome and Immunoproteasome
Subunits in FMC Lesions
Twenty-five primary FMCs, including 16 simple tubular carcinomas,
4 simple tubulopapillary carcinomas, 3 simple solid carcinomas, and
1 adenocarcinoma, were immunohistochemically stained with X-, Y-, Z-,
LMP2-, LMP7-, and LMP10-specific mAb and with MHC class I
HC-specific mAb. Normal lymphocytes and vessel endothelia were
used in each specimen as internal controls. This analysis showed that
the expression of X, Y, Z, and LMP10 in the neoplastic component of
the lesion was similar to that in the corresponding healthy mammary
tissue in 96% and in 92% of the cases evaluated for proteasome sub-
units and for the immunoproteasome subunit LMP10, respectively Ta
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(Table 1). On the contrary, tumor lesions were found to have a highly
variable expression profile ranging from a total loss, to heterogeneous
but decreased expression levels, to normal expression for LMP2, LMP7,
and MHC class I HC (Table 1 and Figure 2). The expression of MHC
class I HC and IFN-γ–induced catalytic subunits LMP2 and LMP7
was reduced in tumor lesions compared with matched healthy tissues.
As shown in Table 1, among the seven proteins examined, MHC class I
HC and LMP7 showed the greatest reduction in expression, being not
detectable in 32% and 40% of the lesions, respectively, and down-
regulated in 44% and 32% of the lesions, respectively. X showed the
smallest reduction, being positive in 96% and downregulated in only 4%
of the lesions. LMP2 was not detectable in 20% and downregulated in
48% of the FMC lesions. Y, Z, and LMP10 were positive in 92% and
downregulated in 8% of the lesions. Taken together, these results clearly
demonstrate that, compared with healthy mammary tissues, mammary
carcinomas did not differ in the expression levels of the proteasome sub-
units X, Y, and Z but displayed a down-regulation of the two immuno-
proteasome subunits LMP2 and LMP7 and of MHC class I HC.
Additional analyses tested whether the expression level of APM
components is correlated to that of MHC class I HC. Analysis by the
Spearman rank correlation coefficient showed that LMP2 and LMP7
expression was significantly correlated with that of MHC class I HC
Figure 2. Immunohistochemical staining patterns of formalin-fixed, paraffin-embedded primary FMC lesions with MHC class I antigen
and APM component-specific mAbs. The staining with MHC class I HC-specific mAb (A and B), with LMP2-specific mAb (C and D), with
LMP7-specific mAb (E and F) andwith LMP10-specific mAb (G and H) was scored as positive (A, C, E, and G) and as negative (B, D, F, and H),
respectively. Normal lymphocytes, which serve as the internal control, are stained as well (arrow). Original magnification, ×200.
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(r = 0.43, P = .017 and r = 0.70, P < .0001, respectively). Interestingly,
LMP2 and LMP7 are concordantly expressed in FMCs (r = 0.58, P =
.001), suggesting that they are regulated by similar mechanisms.
Enhanced Proteasomal Activity in
Feline Mammary Carcinoma
To investigate whether the down-regulation of IFN-γ–induced cat-
alytic subunits, LMP2 and LMP7, detected by immunohistochemistry
had functional relevance, we next analyzed the cleavage specificity of
proteasomes in homogenates of FMCs and related healthy mammary
tissues by means of specific fluorogenic substrates. By this approach, we
demonstrated that chymotrypsin-like activity, the main proteasomal
proteolytic activity which is rate limiting in protein degradation, is nearly
three-fold higher in FMCs than in healthy mammary tissues (Table 2
and Figure 3A; Z = −2.521 P = .012, Wilcoxon test). In addition,
caspase-like activity was significantly enhanced in FMCs albeit to a
lesser extent (Table 2 and Figure 3B; Z = −2.536 P = .011, Wilcoxon
test). Together, these results demonstrate that chymotrypsin and caspase-
like activities of proteasomes are increased in extracts from FMCs.
In line with the findings of our study, it is generally assumed that
inflammatory cells constitutively express immunoproteasome catalytic
subunits (Figure 2) [2]. Therefore, to determine whether the enhanced
proteasomal activity detected in FMCs resulted from the constitutively
expression of LMP2, LMP7, and LMP10 in inflammatory cells infiltrat-
ing the tumor, we next analyzed the expression of immunoproteasomes
catalytic β subunits in total homogenates of FMCs and related healthy
mammary tissues. To this purpose, tissue extracts from two surgically
removed mammary gland lesions (scored as negative in immuno-
histochemistry analysis for LMP2 and LMP7 expression in tumoral
cells) and matched healthy tissues were analyzed by Western blot anal-
ysis using specific antibodies for immunoproteasomal catalytic β sub-
units. This analysis showed (Figure 4) an enhanced expression of
LMP2, LMP7, and LMP10 in the neoplastic component compared with
corresponding healthy tissue in all evaluated cases. Taken together, these
results clearly demonstrate that three important components of the
APM strongly induced by γ-interferon are expressed at significantly
higher levels in total homogenates of FMCs than in healthy mammary
gland epithelium. These data corroborate the hypothesis that the enhanced
proteasomal proteolytic activity observed in homogenates from FMCs
may be due to tumor infiltration by inflammatory cells, which consti-
tutively express immunoproteasome catalytic subunits.
Discussion
Immunohistochemical staining of surgically removed FMCs and sur-
rounding autologous normal mammary tissue with mAb has shown
defects in the expression of MHC class I HC and of the immuno-
proteasome subunits LMP2 and LMP7 in at least 32% of the lesions
analyzed. In contrast, the expression of the proteasome subunits X, Y,
and Z and of the immunoproteasome subunit LMP10 in FMCs was
similar to that in normal mammary tissues in most lesions tested. To
the best of our knowledge, this is the first report to analyze the expres-
sion of MHC class I HC and proteasome and immunoproteasome
subunits in FMCs. Furthermore, the present study is the first one
to show that changes in LMP2 and LMP7 expression have functional
relevance because proteasomal cleavage specificities in extracts from
FMCs were different from those in the autologous healthy tissues.
The up-regulation of the proteasomal chymotrypsin- and to a lesser
Figure 3. Increase in proteasomal chymotrypsin-like activity and
caspase-like activity in tissue extracts from mammary carcinomas
compared with healthy mammary epithelium. Chymotrypsin-like
activity (A) is nearly three-fold higher in FMCs than in healthy mam-
mary tissues. In addition, caspase-like activity (B) was significantly
enhanced in FMCs albeit to a lesser extent.
Figure 4. Enhanced APM component expression in surgically re-
moved FMC lesions compared to matched healthy tissues. Two
representative Western blot analyses of LMP2, LMP7, and LMP10
expression. C indicates carcinomas; H, corresponding healthymam-
mary tissues.
Table 2. Chymotrypsin-like and Caspase-like Activities in Carcinoma Lesions and Related Healthy Tissue.
Healthy Mammary Tissue Feline Mammary Carcinoma
Chymotrypsin-like activity (nmol Suc-LLVY-AMC cleaved/mg min) 0.139 ± 0.013 (0.141) 0.398 ± 0.116 (0.273)
Caspase-like activity (nmol Z-YVAS-AMC cleaved/mg min) 0.003 ± 0.0005 (0.0025) 0.011 ± 0.004 (0.0055)
Data are presented as the mean ± SEM (median) of the specific activities of all animals analyzed.
SEM, standard error of the mean.
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extent caspase-like activities found in homogenates from FMCs com-
pared with healthy mammary tissues was unexpected because of the
down-regulation of two immunoproteasome subunits found in FMCs.
This apparent paradox may reflect an up-regulation of the constitutive
proteasome catalytic subunits (X, Y, and Z) in the neoplastic tissue,
perhaps to compensate for the down-regulation of the immunoprotea-
some subunits. Expression of the X and Y genes is reciprocal to that of
the LMP genes: X and Y are upregulated in mutant cell lines lacking
LMPs [28]. In this regard, it is noteworthy that our immunohisto-
chemical analysis evaluated the number of stained tumor cells in the
entire lesion but did not evaluate the staining intensity at the level of
single-stained tumoral cells. Therefore, in tumor lesions, an increased
expression of constitutive proteasome catalytic subunits cannot be ex-
cluded. An additional mechanism contributing to the enhanced protea-
somal proteolytic activity observed in homogenates from FMCs may be
represented by the infiltration of tumors with inflammatory cells, which
constitutively express immunoproteasome catalytic subunits (Figure 2)
[2]. Immunoblot analysis supports this hypothesis: tissue extracts from
two surgically removed mammary gland lesions, scored in immuno-
histochemistry analysis as negative for LMP2 and LMP7 expression
in tumoral cells, on the contrary by Western blot analysis showed an
enhanced expression of immunoproteasome catalytic subunits com-
pared with healthy mammary tissues. In line with our results, defective
expression of MHC class I antigens and APM components has been
demonstrated in almost all works by immunohistochemistry analysis
because this technique allows to discriminate between inflammatory
and tumoral cells [31,32,36].
The changes in the proteasomal cleavage specificities found in ex-
tracts from FMCs argue in favor of the possibility that LMP2 and
LMP7 down-regulation in FMCs affects the repertoire of TA-derived
peptides expressed by tumor cells. Whether these changes influence
the recognition of mammary tumor cells by MHC class I antigen-
restricted, TA-derived peptide-specific T cells remains to be investi-
gated. Should this be the case, cats with mammary tumors represent
a useful model to investigate the contribution of immunoproteasome
subunit defects to escape mechanisms used by tumor cells to avoid
recognition and destruction by MHC class I antigen-restricted, TA-
specific cytotoxic T lymphocyte. Furthermore, cats with mammary
tumors may represent useful models to develop and test strategies to
counteract escape mechanisms caused by changes in the expression
and functional properties of immunoproteasome subunits.
The expression of immunoproteasome and proteasome subunits
has been investigated in human mammary tumors. The phenotype
of FMCs we have described resembles that of human breast carci-
noma lesions as Gobbi et al. [29] found a down-regulation of LMP2
and MHC class I HC in 51.4% and 40.0% of the lesions tested,
respectively. Whereas all normal tissues and benign lesions were posi-
tive for β2-m andHLA class I HC, total loss of HLA class I antigens was
found in 43% of the breast primary tumors and in 70% of the lymph
node metastases [30]. To the best of our knowledge, the expression
of immunoproteasome subunits has been described in a number of
human solid tumors, whereas that of proteasome subunits has been
investigated in a much lower number of solid tumors. The frequency
of LMP2 and LMP7 down-regulation we have found in FMCs is sim-
ilar to that described in renal, cervical, and head and neck carcinomas
[15,20,31]. In addition, an unbalanced expression of LMP2, LMP7, and
LMP10 has been described in many human solid tumors [20,34,35].
Nevertheless, the expression of proteasome subunits has been described
only in human brain and bladder carcinomas [32,33]. As we have
described in this study, the X, Y, and Z housekeeping proteasomal sub-
units, the LMP10 immunoproteasomal subunit, were detected in most
medulloblastoma and astrocytic tumor lesions [32].
It is generally assumed that immunoproteasome subunits expres-
sion is constitutive only in immunologic cells, whereas it is induced in
other cells on exposure to cytokines (i.e., IFN-γ), thereby increasing
the number of peptides capable of binding MHC class I antigens [5].
At variance with this notion, we observed basal expression of LMP2,
LMP7, and LMP10 in normal mammary epithelial cells. In fact,
LMP2, LMP7, and LMP10 seem coordinately expressed in all healthy
mammary tissues tested in our study. It should be stressed that the
expression of immunoproteasome subunits in nonimmune cells under
basal conditions is not unique to feline mammary tissue because it has
also been described in human mammary, renal, laryngeal, neural,
bladder, prostate, and cervical tissues [15,18,20,29,32–36].
From a methodological view point, it is noteworthy that the pres-
ent study is one of the very few ones that compare the expression of
MHC class I HC in malignant cells and autologous surrounding tis-
sues. To the best of our knowledge, a similar comparison has been
done only in a study that analyzed the expression of APM compo-
nents in bladder carcinoma cells and in surrounding normal cells.
The conclusions from these studies about changes in the expression
of APM components in malignant cells are more meaningful than
those derived from most of the published studies, including our
own, which assess the expression of these molecules in malignant cells
by comparison with the endothelial cells and lymphoid cells present in
the tissue section analyzed [36].
In summary, this study provides the first description of changes in
the expression and function of MHC class I–related APM components
in FMCs. Characterization of the role of these changes in the interac-
tions of FMCs with the host immune system may contribute to our
understanding of the molecular mechanisms used by tumor cells and
may suggest targeted strategies to counteract these escape mechanisms.
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